Business Context and Reporting Period
This Form 6-K filing by Evaxion Biotech A/S covers the month of December 2024. The report details a material modification to the rights of security holders approved by the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and capital structure changes rather than financial performance.
Material Changes
The primary material change is the modification of the American Depositary Share (ADS) ratio:
- Previous Ratio: 1 ADS represented 10 ordinary shares.
- New Ratio: 1 ADS will represent 50 ordinary shares.
- Effective Date: Expected on or about January 13, 2025.
- Mechanism: The change functions as a one-for-five reverse ADS split. Holders of certificated ADSs must surrender them for cancellation and receive one new ADS for every five existing ADSs. Uncertificated ADSs will be automatically exchanged.
Outlook, Risks, and Management Commentary
Management intends for the ADS Ratio Change to further support liquidity in the Company's ADSs. The Company notes the following risks and expectations:
- Price Impact: The ADS trading price is expected to increase proportionally, though the Company provides no assurance that the post-change price will be proportionally equal to or greater than the pre-change price.
- Liquidity: There is no assurance that the Ratio Change will have any effect on the liquidity of the Company's ADSs.
- Fractional Shares: No fractional new ADSs will be issued. Fractional entitlements will be aggregated, sold by the Depositary, and net cash proceeds distributed to holders after fees and taxes.
- Trading Symbol: ADSs will continue to trade on The Nasdaq Capital Market under the ticker symbol "EVAX."
Investor Verification Checklist
- Confirm the exact effective date of the ADS Ratio Change (expected January 13, 2025).
- Verify the specific procedures for surrendering certificated ADSs versus the automatic exchange of uncertificated ADSs.
- Monitor the post-split trading price to assess if it aligns with the expected proportional increase.
- Review the press release (Exhibit 99.1) for any additional details on the rationale for the reverse split.